• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    January 8, 2021 - Coronavirus (COVID-19) Update: January 8, 2021

    1/8/21 3:42:09 PM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary
    Get the next $RH alert in real time by email
    For Immediate Release:
    January 08, 2021

    The U.S. Food and Drug Administration (FDA) continued to take action in the ongoing response to the COVID-19 pandemic:

    • The FDA alerted clinical laboratory staff and health care providers that genetic variants of SARS-CoV-2 may lead to false negative results with molecular tests for SARS-CoV-2. The Letter to Clinical Laboratory Staff and Health Care Providers includes important information about potential false negative results with molecular tests, including:
      • Details on the effect of genetic variants on test performance.
      • Recommendations for clinical laboratory staff and health care providers.
      • Actions the FDA has taken.  
      • Instructions for reporting problems with a test. 
    • This week, the FDA posted a new webpage, Moderna COVID-19 Vaccine Frequently Asked Questions. Questions cover specifics, such as what data did the FDA review when deciding whether to authorize the vaccine for emergency use, how well the vaccine prevents COVID-19, and more.
    • A U.S. District Court in Georgia granted a consent decree of permanent injunction against Fusion Health and Vitality LLC, Fusion Ionz LLC and Matthew Ryncarz for violating federal law by distributing products containing vitamin D and hordenine HCl, as preventions or treatments for COVID-19. The order of permanent injunction that the Court issued permanently prohibits the defendants from, among other things, selling or distributing unapproved new drugs or misbranded drugs with claims that the products can cure, mitigate, treat or prevent diseases in people, including COVID-19.  In addition, the injunction permanently prohibits defendants from selling or distributing dietary supplements containing hordenine HCl because hordenine HCl is an unsafe food additive. In May, FDA issued a warning letter to the defendants for fraudulently promoting violative products on a number of websites. In the warning letter, the FDA requested that they immediately correct their violations, which they did not do.  
      • “Americans expect and deserve medical treatments that have been scientifically proven to be safe and effective. Making claims that unproven drugs can cure or prevent diseases, including COVID-19, places consumers’ health at risk,” said FDA Chief Counsel Stacy Amin. “We remain committed to pursuing and taking swift action against those who attempt to subvert the regulatory functions of the FDA by repeatedly disregarding the law and distributing unapproved products.” 
      • The FDA is particularly concerned that fraudulent products that claim to cure, mitigate, treat or prevent serious diseases like COVID-19 may cause consumers to delay or stop appropriate medical treatment, leading to serious and life-threatening harm. The FDA reminds the public to seek medical help from their health care providers and urges people to talk to their health care provider about treatment options.
    • Testing updates:
      • As of today, 311 tests and sample collection devices are authorized by the FDA under emergency use authorizations (EUAs). These include 235 molecular tests and sample collection devices, 64 antibody tests, and 12 antigen tests. There are 32 molecular authorizations that can be used with home-collected samples. There is one molecular prescription at-home test, one antigen prescription at-home test, and one over-the-counter (OTC) at-home antigen test.
         

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

    ###


    Inquiries

    Media:
    Courtney Rhodes
    888-INFO-FDA
    Consumer:
    888-INFO-FDA

    Related Information

    Related Information

    •    COVID-19 Vaccines
    •    Coronavirus Disease 2019 (COVID-19)


    Get the next $RH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RH

    DatePrice TargetRatingAnalyst
    3/25/2026$185.00 → $165.00Market Perform
    Telsey Advisory Group
    12/12/2025$165.00Buy → Hold
    Stifel
    12/12/2025$220.00 → $185.00Market Perform
    Telsey Advisory Group
    10/2/2025Outperform → Mkt Perform
    William Blair
    9/12/2025$220.00Outperform → Market Perform
    Telsey Advisory Group
    6/24/2025$179.00Neutral → Sell
    Goldman
    6/9/2025$280.00 → $255.00Outperform
    Telsey Advisory Group
    4/3/2025$410.00 → $130.00Buy → Underperform
    BofA Securities
    More analyst ratings

    $RH
    SEC Filings

    View All

    SEC Form 10-K filed by RH

    10-K - RH (0001528849) (Filer)

    3/31/26 6:58:16 PM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    RH filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - RH (0001528849) (Filer)

    3/31/26 4:20:45 PM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by RH

    SCHEDULE 13G/A - RH (0001528849) (Subject)

    3/27/26 11:37:34 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    $RH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RH Reports Fourth Quarter and Fiscal Year 2025 Results

    RH (NYSE:RH) announced that it released financial results for the fourth quarter and fiscal year 2025 ended January 31, 2026, and posted an accompanying video presentation from Gary Friedman, RH Chairman and Chief Executive Officer, highlighting the Company's continued evolution, recent performance and outlook on the Investor Relations section of the Company's website at ir.rh.com. As previously announced, RH leadership will host a live audio webcast at 2:00 pm Pacific Time (5:00 pm Eastern Time) today at ir.rh.com. A replay of the webcast can also be accessed at ir.rh.com. ABOUT RH RH (NYSE:RH) is a global curator of design, taste and style in the luxury lifestyle market. Operating a

    3/31/26 4:06:00 PM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    RH Announces the Appointment of Veronica Schnitzius as President, Chief Manufacturing & Sourcing Officer

    RH (NYSE:RH) announced today that Veronica Schnitzius is joining the Company as President, Chief Manufacturing & Sourcing Officer. Veronica will lead RH's efforts to build a global manufacturing platform that combines owned and operated, joint-ventured, and outsourced manufacturing for the Company's core furniture business, which represents 80% of RH brand revenues. The strategy will emulate the vertically integrated model of many of the world's largest and most profitable luxury brands that have a high level of control over the manufacturing, quality and capacity of their core business. Mrs. Schnitzius joins RH after a distinguished 24-year career at American Leather, a leading U.S. br

    3/27/26 8:00:00 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    RH Announces the Appointment of David Stanchak as Chief Real Estate and Transformation Officer

    RH (NYSE:RH) today announced that David Stanchak has returned to the Company as Chief Real Estate and Transformation Officer. Mr. Stanchak has resumed his role leading the Company's Global Real Estate Expansion and North American Gallery Transformation, a position he held from May 2015 through May 2021. Mr. Stanchak will also be leading efforts to monetize the Company's significant portfolio of real estate assets in the United States and Europe. RH Chairman and Chief Executive Officer, Gary Friedman commented, "We are thrilled Dave is rejoining Team RH. His leadership expanding our Gallery platform globally, transforming our legacy stores into Design Galleries with integrated Restaurant

    3/26/26 5:49:00 PM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    $RH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chaya Eri

    4 - RH (0001528849) (Issuer)

    4/1/26 8:00:07 PM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    SEC Form 4 filed by Hargarten Christina

    4 - RH (0001528849) (Issuer)

    4/1/26 8:00:09 PM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    SEC Form 4 filed by Chaya Eri

    4 - RH (0001528849) (Issuer)

    3/25/26 8:00:08 PM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    $RH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHAIRMAN & CEO Friedman Gary G bought $9,999,978 worth of shares (46,274 units at $216.10), increasing direct ownership by 1% to 3,351,337 units (SEC Form 4)

    4 - RH (0001528849) (Issuer)

    6/27/24 7:47:18 PM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    $RH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Telsey Advisory Group reiterated coverage on RH with a new price target

    Telsey Advisory Group reiterated coverage of RH with a rating of Market Perform and set a new price target of $165.00 from $185.00 previously

    3/25/26 8:14:41 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    RH downgraded by Stifel with a new price target

    Stifel downgraded RH from Buy to Hold and set a new price target of $165.00

    12/12/25 8:43:14 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    Telsey Advisory Group reiterated coverage on RH with a new price target

    Telsey Advisory Group reiterated coverage of RH with a rating of Market Perform and set a new price target of $185.00 from $220.00 previously

    12/12/25 8:16:25 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    $RH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

    Submission status for RHODES PHARMS's drug DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE (ORIG-1) with active ingredient AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE has changed to 'Approval' on 01/13/2021. Application Category: ANDA, Application Number: 213111, Application Classification:

    1/18/21 5:24:40 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    FDA Approval for DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

    Submission status for RHODES PHARMS's drug DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE (ORIG-1) with active ingredient AMPHETAMINE ASPARTATE ; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE has changed to 'Approval' on 01/13/2021. Application Category: ANDA, Application Number: 213111, Application Classification:

    1/18/21 5:24:40 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    FDA Approval for DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

    Submission status for RHODES PHARMS's drug DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE (ORIG-1) with active ingredient AMPHETAMINE ASPARTATE ; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE has changed to 'Approval' on 01/15/2021. Application Category: ANDA, Application Number: 213111, Application Classification:

    1/15/21 11:16:15 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    $RH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by RH

    SC 13G/A - RH (0001528849) (Subject)

    11/14/24 5:05:51 PM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by RH

    SC 13G/A - RH (0001528849) (Subject)

    11/14/24 4:15:30 PM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by RH

    SC 13G/A - RH (0001528849) (Subject)

    11/12/24 10:34:15 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    $RH
    Financials

    Live finance-specific insights

    View All

    RH to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 31, 2026

    RH (NYSE:RH) today announced that it will report financial results for the fourth quarter and fiscal year 2025 ended January 31, 2026, on Tuesday, March 31, 2026, after market close. RH's fourth quarter and fiscal year 2025 financial results will include a video presentation from Gary Friedman, RH Chairman and Chief Executive Officer, highlighting the Company's continued evolution and recent performance. The video presentation will be posted to the Company's investor relations website at ir.rh.com. RH leadership will host a live webcast of the video presentation followed by Q&A at 2:00 pm Pacific Time (5:00 pm Eastern Time) on March 31, 2026, at ir.rh.com. A replay will also be available

    3/26/26 4:05:00 PM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    RH Reports Third Quarter Fiscal 2025 Results

    RH (NYSE:RH) has released its financial results for the third quarter ended November 1, 2025, in a shareholder letter from Chairman and Chief Executive Officer Gary Friedman, available on the Investor Relations section of its website at ir.rh.com. As previously announced, RH leadership will host a live conference call and audio webcast at 2:00 pm Pacific Time (5:00 pm Eastern Time) today. The live conference call may be accessed by dialing 800.715.9871 or 646.307.1963 for international callers (conference ID: 8284432). The call and replay can also be accessed via audio webcast at ir.rh.com. ABOUT RH RH (NYSE:RH) is a global curator of design, taste and style in the luxury lifestyle marke

    12/11/25 4:46:00 PM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    RH to Report Third Quarter Fiscal 2025 Financial Results on December 11, 2025

    RH (NYSE:RH) today announced that it will report financial results for the third quarter ended November 1, 2025, on Thursday, December 11, 2025, after market close. RH's third quarter fiscal 2025 financial results press release will include a shareholder letter from Chairman and Chief Executive Officer, Gary Friedman, highlighting the Company's continued evolution and recent performance. The shareholder letter and financial results will be posted to the Company's investor relations website at ir.rh.com. RH leadership will host a live conference call and audio webcast at 2:00 pm Pacific Time (5:00 pm Eastern Time) on December 11, 2025. The live conference call may be accessed by dialing 800

    12/4/25 4:05:00 PM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    $RH
    Leadership Updates

    Live Leadership Updates

    View All

    RH Announces the Appointment of Veronica Schnitzius as President, Chief Manufacturing & Sourcing Officer

    RH (NYSE:RH) announced today that Veronica Schnitzius is joining the Company as President, Chief Manufacturing & Sourcing Officer. Veronica will lead RH's efforts to build a global manufacturing platform that combines owned and operated, joint-ventured, and outsourced manufacturing for the Company's core furniture business, which represents 80% of RH brand revenues. The strategy will emulate the vertically integrated model of many of the world's largest and most profitable luxury brands that have a high level of control over the manufacturing, quality and capacity of their core business. Mrs. Schnitzius joins RH after a distinguished 24-year career at American Leather, a leading U.S. br

    3/27/26 8:00:00 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    RH Announces the Appointment of David Stanchak as Chief Real Estate and Transformation Officer

    RH (NYSE:RH) today announced that David Stanchak has returned to the Company as Chief Real Estate and Transformation Officer. Mr. Stanchak has resumed his role leading the Company's Global Real Estate Expansion and North American Gallery Transformation, a position he held from May 2015 through May 2021. Mr. Stanchak will also be leading efforts to monetize the Company's significant portfolio of real estate assets in the United States and Europe. RH Chairman and Chief Executive Officer, Gary Friedman commented, "We are thrilled Dave is rejoining Team RH. His leadership expanding our Gallery platform globally, transforming our legacy stores into Design Galleries with integrated Restaurant

    3/26/26 5:49:00 PM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    RH Announces the Appointment of Lisa Chi as President, Co-Chief Merchandising & Creative Officer

    RH announced today the appointment of Lisa Chi as President, Co-Chief Merchandising & Creative Officer reporting to RH Chairman & CEO Gary Friedman. Lisa will co-lead Product Development, Merchandising, Inventory Planning, Sourcing, Manufacturing, and Marketing, across the Company's Physical, Print, and Digital Platforms with Eri Chaya, RH President, Co-Chief Merchandising & Creative Officer and member of the RH Board of Directors. "We are honored to welcome Lisa back to Team RH as we continue to elevate and expand our product and platform," commented RH Chairman & CEO Gary Friedman. "Lisa's accomplishments while at Arhaus were impressive as she led the merchandising organization during a

    5/20/25 6:45:00 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary